Aug 23 (Reuters) - Intra-cellular Therapies Inc
* Intra-Cellular Therapies announces positive regulatory update on schizophrenia program
* Intra-Cellular Therapies Inc- U.S. FDA has informed company that FDA has completed its review of company’s responses to requests from FDA
* Intra-Cellular Therapies-requests from FDA relate to information regarding some findings in nonclinical toxicology studies of lumateperone in animals
* Intra-Cellular Therapies-FDA agrees that co presented adequate data to support position metabolic pathway in animal species is distinctive from humans
* Intra-Cellular Therapies-moving forward with long-term safety study of lumateperone, intends to submit NDA for treatment of schizophrenia by mid-2018 Source text for Eikon: Further company coverage:
